Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

Rheumatology and Therapy
David M KernAndre B Araujo

Abstract

To describe treatment patterns in newly diagnosed rheumatoid arthritis (RA) patients in a large, nationally representative managed-care database. Newly diagnosed RA patients were identified from 07/01/2006-08/31/2014. Patients had ≥ 1 RA diagnosis by a rheumatologist, or ≥ 2 non-rheumatologist RA diagnoses ≥ 30 days apart, or RA diagnosis followed by a disease-modifying antirheumatic drug (DMARD) prescription fill within 1 year. Patients were ≥ 18 years old at index (earliest date fulfilling diagnostic criteria) and had ≥ 6 and 12 months of pre- and post-index health plan enrollment, respectively. Patterns of DMARD treatment, including conventional synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus kinase inhibitors (JAKi), were captured during follow-up. Of the 63,101 RA patients identified, 73% were female; mean age was 57 years. During an average of 3.5 ± 2.1 years of follow-up, 45% of patients never received a DMARD, 52% received a csDMARD (94 ± 298 mean ± SD days from index), 16% a TNFi (315 ± 448 days), 4% a non-TNFi (757 ± 660 days), and < 1% a JAKi. Among DMARD recipients, the most common treatment patterns were: receiving csDMARDs only (68%), adding a TNFi as second-line therapy af...Continue Reading

References

Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·M M WardE H Yelin
Sep 26, 2006·Joint, Bone, Spine : Revue Du Rhumatisme·Khalid M KamalVirginia Scott
Jan 1, 2008·Arthritis and Rheumatism·Charles G HelmickUNKNOWN National Arthritis Data Workgroup
Sep 1, 2009·Pharmacoepidemiology and Drug Safety·Denise BoudreauConstance Weisner
Nov 17, 2009·Current Medical Research and Opinion·Howard BirnbaumMary Cifaldi
May 11, 2010·The Journal of Pain : Official Journal of the American Pain Society·Razmic S GregorianShane Kavanagh
May 15, 2010·International Journal of Dermatology·Siamak Moghadam-Kia, Victoria P Werth
Feb 3, 2011·JAMA : the Journal of the American Medical Association·Gabriela SchmajukJinoos Yazdany
Feb 25, 2011·Arthritis Research & Therapy·Seo Young KimDaniel H Solomon
May 25, 2012·Arthritis Care & Research·Bernard NgMaria E Suarez-Almazor
Feb 20, 2013·Nature Reviews. Rheumatology·John J O'SheaIain B McInnes
May 28, 2013·Journal of Opioid Management·Kathryn P AnastassopoulosMyoung S Kim
Oct 2, 2013·Seminars in Arthritis and Rheumatism·Maurizio CutoloPiet L C M van Riel
Nov 8, 2015·Arthritis Care & Research·Jasvinder A SinghTimothy McAlindon
Nov 8, 2015·Arthritis & Rheumatology·Jasvinder A SinghTimothy McAlindon
Mar 20, 2016·Current Opinion in Chemical Biology·Kunihiro Yamaoka
Mar 31, 2016·The Journal of Primary Prevention·James A Mercy, Alana M Vivolo-Kantor
Mar 31, 2016·The New England Journal of Medicine·Mark C GenoveseJosef S Smolen

❮ Previous
Next ❯

Citations

Jun 19, 2019·Current Pharmaceutical Design·Allison B ReissJoshua De Leon
Sep 11, 2019·Journal of Clinical Medicine·Bogdan BatkoZbigniew Żuber
Apr 10, 2020·Current Medical Research and Opinion·Jessica A WalshSoumya D Chakravarty
Mar 15, 2019·Current Opinion in Rheumatology·Alvin Lee Day, Jeffrey R Curtis
Mar 2, 2019·PloS One·Ana Paula Monteiro GomidesGeraldo da Rocha Castelar Pinheiro
Oct 17, 2019·The Journal of Rheumatology·Paula MuiluKari Puolakka
Mar 28, 2019·Journal of Managed Care & Specialty Pharmacy·Ibrahim KhilfehKai Yeung
Jul 28, 2019·Journal of Managed Care & Specialty Pharmacy·Natalie N BoytsovRadhika Nair
Feb 27, 2020·JAMA Network Open·Kalyani SonawaneMaria E Suarez-Almazor
Feb 26, 2021·British Journal of Clinical Pharmacology·Juliana de Oliveira CostaSallie-Anne Pearson
Jun 20, 2021·Journal of Biomedical Informatics·Mohammad Amin MoridGuilherme Del Fiol
Jan 26, 2022·Rheumatology and Therapy·Eory Madera MirandaManasi Suryavanshi

❮ Previous
Next ❯

Software Mentioned

SAS Enterprise Guide

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.